What's Happening?
Stoke Therapeutics has announced promising results from its ongoing studies on zorevunersen, an investigational treatment for Dravet syndrome. The company released new 4-year longitudinal data from Phase
1/2a open-label extension studies, showing significant improvements in cognition and behavior, as well as sustained seizure reduction. The data supports zorevunersen's potential as a disease-modifying treatment. The Phase 3 EMPEROR study is nearing completion, with enrollment expected to finish by June 2026, and a data readout anticipated in mid-2027. Financially, Stoke reported a net loss of $50 million for the first quarter of 2026, with $411 million in cash reserves expected to fund operations into 2028.
Why It's Important?
The development of zorevunersen is significant as it offers hope for a disease-modifying therapy for Dravet syndrome, a severe form of epilepsy with limited treatment options. The positive data could lead to a new standard of care, improving the quality of life for patients and their families. The financial stability of Stoke Therapeutics, with substantial cash reserves, positions the company well to continue its research and development efforts. Successful completion of the Phase 3 study and subsequent FDA approval could lead to a new market entrant, potentially impacting the competitive landscape in the treatment of genetic epilepsies.
What's Next?
Stoke Therapeutics plans to complete the enrollment for the Phase 3 EMPEROR study by June 2026, with a data readout expected in mid-2027. The company aims to initiate a rolling New Drug Application submission to the FDA in early 2027. If successful, zorevunersen could be launched in the U.S. by early 2028. Stoke is also focusing on commercial preparedness and expanding its pipeline, supported by its strong financial position.
